Michael DiStefano
Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Negotiating | 5 | 2025 | 34 | 2.610 |
Why?
| | Morals | 4 | 2024 | 84 | 2.350 |
Why?
| | Medicare | 6 | 2025 | 907 | 2.310 |
Why?
| | Technology Assessment, Biomedical | 7 | 2026 | 44 | 1.890 |
Why?
| | Cost-Benefit Analysis | 8 | 2025 | 632 | 1.680 |
Why?
| | Direct-to-Consumer Advertising | 2 | 2024 | 8 | 1.600 |
Why?
| | Medicare Part D | 3 | 2023 | 23 | 1.560 |
Why?
| | Drug Costs | 6 | 2026 | 115 | 1.440 |
Why?
| | Alzheimer Disease | 3 | 2024 | 640 | 1.410 |
Why?
| | Health Priorities | 4 | 2026 | 45 | 1.310 |
Why?
| | Prescription Drugs | 2 | 2023 | 110 | 1.270 |
Why?
| | Drug Industry | 2 | 2026 | 46 | 0.970 |
Why?
| | Health Facility Closure | 1 | 2025 | 8 | 0.910 |
Why?
| | Drug Compounding | 1 | 2026 | 106 | 0.910 |
Why?
| | Anti-Obesity Agents | 1 | 2026 | 67 | 0.900 |
Why?
| | Pharmacies | 1 | 2025 | 40 | 0.880 |
Why?
| | Community Pharmacy Services | 1 | 2025 | 46 | 0.880 |
Why?
| | Glucagon-Like Peptides | 1 | 2026 | 76 | 0.840 |
Why?
| | Health Care Rationing | 1 | 2024 | 53 | 0.840 |
Why?
| | Bioethics | 2 | 2024 | 26 | 0.830 |
Why?
| | Comparative Effectiveness Research | 2 | 2025 | 170 | 0.800 |
Why?
| | Social Values | 2 | 2023 | 40 | 0.790 |
Why?
| | United States | 20 | 2026 | 16041 | 0.770 |
Why?
| | Pregnancy in Diabetics | 1 | 2024 | 123 | 0.740 |
Why?
| | Medicare Part C | 1 | 2023 | 38 | 0.730 |
Why?
| | Public Opinion | 1 | 2022 | 61 | 0.690 |
Why?
| | Pharmaceutical Preparations | 1 | 2023 | 172 | 0.660 |
Why?
| | Health Equity | 1 | 2023 | 139 | 0.630 |
Why?
| | Hypoglycemic Agents | 2 | 2026 | 1411 | 0.600 |
Why?
| | Qualitative Research | 2 | 2025 | 1720 | 0.600 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2024 | 704 | 0.570 |
Why?
| | Social Justice | 1 | 2019 | 82 | 0.550 |
Why?
| | Humans | 38 | 2026 | 145625 | 0.490 |
Why?
| | Social Media | 1 | 2019 | 158 | 0.480 |
Why?
| | Wearable Electronic Devices | 1 | 2017 | 75 | 0.460 |
Why?
| | South Africa | 4 | 2023 | 262 | 0.430 |
Why?
| | Blood Glucose | 1 | 2024 | 2357 | 0.410 |
Why?
| | Health Services Needs and Demand | 2 | 2026 | 283 | 0.410 |
Why?
| | Public Health | 1 | 2018 | 573 | 0.380 |
Why?
| | Policy | 2 | 2024 | 147 | 0.350 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2026 | 2623 | 0.350 |
Why?
| | Aged | 11 | 2026 | 26251 | 0.340 |
Why?
| | Cross-Sectional Studies | 5 | 2026 | 5875 | 0.330 |
Why?
| | Economics, Pharmaceutical | 2 | 2019 | 10 | 0.300 |
Why?
| | Biosimilar Pharmaceuticals | 2 | 2026 | 28 | 0.280 |
Why?
| | Decision Making | 3 | 2026 | 987 | 0.280 |
Why?
| | Depression | 1 | 2018 | 1566 | 0.270 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 3930 | 0.260 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2025 | 992 | 0.260 |
Why?
| | Surveys and Questionnaires | 3 | 2026 | 6050 | 0.250 |
Why?
| | Oklahoma | 1 | 2026 | 21 | 0.240 |
Why?
| | Ethical Analysis | 1 | 2026 | 6 | 0.240 |
Why?
| | Pharmacy Technicians | 1 | 2025 | 1 | 0.230 |
Why?
| | Cost Sharing | 1 | 2026 | 23 | 0.230 |
Why?
| | Costs and Cost Analysis | 2 | 2023 | 216 | 0.230 |
Why?
| | Genetic Therapy | 2 | 2025 | 303 | 0.230 |
Why?
| | Utah | 1 | 2025 | 82 | 0.220 |
Why?
| | Health Services Accessibility | 2 | 2025 | 1101 | 0.220 |
Why?
| | Biomedical Technology | 2 | 2022 | 49 | 0.220 |
Why?
| | Focus Groups | 2 | 2025 | 587 | 0.220 |
Why?
| | Cost Savings | 1 | 2024 | 85 | 0.210 |
Why?
| | Reimbursement Mechanisms | 1 | 2025 | 78 | 0.210 |
Why?
| | Germany | 1 | 2024 | 139 | 0.200 |
Why?
| | Quality-Adjusted Life Years | 1 | 2024 | 119 | 0.200 |
Why?
| | Medicaid | 2 | 2025 | 472 | 0.200 |
Why?
| | Medicare Part B | 1 | 2023 | 7 | 0.200 |
Why?
| | Technology | 1 | 2024 | 100 | 0.190 |
Why?
| | Adult | 6 | 2026 | 40821 | 0.190 |
Why?
| | National Health Programs | 1 | 2023 | 23 | 0.190 |
Why?
| | Hemophilia B | 1 | 2023 | 65 | 0.190 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2025 | 200 | 0.190 |
Why?
| | Psychotherapy | 1 | 2024 | 179 | 0.190 |
Why?
| | Female | 10 | 2026 | 79080 | 0.180 |
Why?
| | Pharmacists | 1 | 2025 | 260 | 0.180 |
Why?
| | Human Rights | 1 | 2022 | 19 | 0.180 |
Why?
| | Mental Competency | 1 | 2022 | 28 | 0.180 |
Why?
| | Male | 10 | 2026 | 73014 | 0.170 |
Why?
| | Hemophilia A | 1 | 2023 | 149 | 0.170 |
Why?
| | Drug Approval | 1 | 2022 | 93 | 0.170 |
Why?
| | Health Expenditures | 1 | 2023 | 196 | 0.170 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 295 | 0.170 |
Why?
| | United States Food and Drug Administration | 1 | 2022 | 207 | 0.160 |
Why?
| | Middle Aged | 5 | 2026 | 36359 | 0.160 |
Why?
| | Pressure Ulcer | 1 | 2021 | 41 | 0.160 |
Why?
| | Anemia, Sickle Cell | 1 | 2025 | 322 | 0.160 |
Why?
| | Informed Consent | 1 | 2022 | 194 | 0.160 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2021 | 58 | 0.160 |
Why?
| | Patient Positioning | 1 | 2021 | 70 | 0.160 |
Why?
| | Patient Participation | 1 | 2024 | 454 | 0.150 |
Why?
| | Economic Competition | 1 | 2019 | 13 | 0.150 |
Why?
| | Legislation, Drug | 1 | 2019 | 72 | 0.140 |
Why?
| | Public Health Surveillance | 1 | 2019 | 84 | 0.140 |
Why?
| | Civil Disorders | 1 | 2018 | 8 | 0.140 |
Why?
| | Colorado | 2 | 2025 | 4588 | 0.140 |
Why?
| | Cell Phone | 1 | 2019 | 83 | 0.130 |
Why?
| | Chronic Disease | 2 | 2026 | 1824 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2024 | 942 | 0.130 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.130 |
Why?
| | Caregivers | 1 | 2026 | 1079 | 0.130 |
Why?
| | Retrospective Studies | 3 | 2024 | 17291 | 0.130 |
Why?
| | Diabetes Mellitus | 1 | 2026 | 1101 | 0.120 |
Why?
| | Developing Countries | 1 | 2019 | 312 | 0.120 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2024 | 889 | 0.120 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2025 | 1194 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2024 | 3396 | 0.110 |
Why?
| | Violence | 1 | 2018 | 275 | 0.110 |
Why?
| | Infant, Newborn | 1 | 2024 | 6449 | 0.090 |
Why?
| | Cohort Studies | 1 | 2023 | 6045 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2025 | 2674 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 7217 | 0.090 |
Why?
| | Young Adult | 2 | 2026 | 14240 | 0.080 |
Why?
| | Adolescent | 2 | 2026 | 22451 | 0.070 |
Why?
| | Drugs, Generic | 1 | 2026 | 28 | 0.060 |
Why?
| | Stakeholder Participation | 1 | 2026 | 90 | 0.060 |
Why?
| | Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2024 | 6 | 0.050 |
Why?
| | Markov Chains | 1 | 2025 | 128 | 0.050 |
Why?
| | Models, Economic | 1 | 2025 | 63 | 0.050 |
Why?
| | Needs Assessment | 1 | 2026 | 403 | 0.050 |
Why?
| | Health Policy | 1 | 2026 | 399 | 0.050 |
Why?
| | Artificial Intelligence | 1 | 2026 | 385 | 0.040 |
Why?
| | Ontario | 1 | 2019 | 91 | 0.040 |
Why?
| | Japan | 1 | 2019 | 149 | 0.040 |
Why?
| | Public Policy | 1 | 2019 | 79 | 0.040 |
Why?
| | Hospitals | 1 | 2021 | 730 | 0.030 |
Why?
| | Critical Care | 1 | 2021 | 700 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2025 | 8351 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11744 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 10840 | 0.010 |
Why?
| | Child | 1 | 2022 | 22638 | 0.010 |
Why?
|
|
DiStefano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|